These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1376371)

  • 21. Different virus-precipitating activities of neutralizing monoclonal antibodies that recognize distinct sites of poliovirus particles.
    Taniguchi K; Urasawa S
    Arch Virol; 1987; 92(1-2):27-40. PubMed ID: 2432854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes.
    Puligedda RD; Kouiavskaia D; Al-Saleem FH; Kattala CD; Nabi U; Yaqoob H; Bhagavathula VS; Sharma R; Chumakov K; Dessain SK
    Vaccine; 2017 Oct; 35(41):5455-5462. PubMed ID: 28343771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new antigenic site of poliovirus recognized by an intertypic cross-neutralizing monoclonal antibody.
    Uhlig J; Wiegers K; Dernick R
    Virology; 1990 Oct; 178(2):606-10. PubMed ID: 2171198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular basis for linkage of a continuous and discontinuous neutralization epitope on the structural polypeptide VP2 of poliovirus type 1.
    Wiegers KJ; Wetz K; Dernick R
    J Virol; 1990 Mar; 64(3):1283-9. PubMed ID: 1689392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding of neutralizing monoclonal antibodies to empty capsids of poliovirus can be blocked by monospecific antisera to structural polypeptides VP1 and VP2.
    Uhlig H; Haardt F; Dernick R
    Arch Virol; 1985; 83(3-4):295-303. PubMed ID: 2578787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of poliovirus during an outbreak: sequential type 3 poliovirus isolates from several persons show shifts of neutralization determinants.
    Huovilainen A; Hovi T; Kinnunen L; Takkinen K; Ferguson M; Minor P
    J Gen Virol; 1987 May; 68 ( Pt 5)():1373-8. PubMed ID: 2437244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A neutralizing monoclonal antibody against poliovirus and its reaction with related antigens.
    Icenogle J; Gilbert SF; Grieves J; Anderegg J; Rueckert R
    Virology; 1981 Nov; 115(1):211-5. PubMed ID: 6270899
    [No Abstract]   [Full Text] [Related]  

  • 28. Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies.
    Emini EA; Kao SY; Lewis AJ; Crainic R; Wimmer E
    J Virol; 1983 May; 46(2):466-74. PubMed ID: 6188863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping of antigenic domains in poliovirus VP1 involved in structural rearrangements during virus morphogenesis and antigenic alterations of the virion.
    Ketterlinus R; Wiegers K
    Virology; 1994 Oct; 204(1):27-37. PubMed ID: 7522372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the location of antigenic sites of swine vesicular disease virus with neutralization-resistant mutants.
    Kanno T; Inoue T; Wang Y; Sarai A; Yamaguchi S
    J Gen Virol; 1995 Dec; 76 ( Pt 12)():3099-106. PubMed ID: 8847515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antigen differences of genetic variants Abent+ and Abent- poliovirus vaccine strain of III type].
    Shyrobokov VP; Kostenko IH; Nikolaienko IV
    Mikrobiol Z; 2003; 65(4):29-36. PubMed ID: 14618784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
    Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
    Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Creation of an antigenic site in poliovirus type 1 by assembly of 14 S subunits.
    Rombaut B; Boeyé A; Ferguson M; Minor PD; Mosser A; Rueckert R
    Virology; 1990 Jan; 174(1):305-7. PubMed ID: 1688474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibodies reveal in blocking reactions the antigenicity and antibody response of poliovirus.
    Uhlig H; Rutter G; Dernick R
    Dev Biol Stand; 1984; 57():187-91. PubMed ID: 6084610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutralization antigenic sites of poliovirus and peptide induction of neutralizing antibodies.
    Emini EA; Wimmer E; Jameson BA; Bonin J; Diamond D
    Ann Sclavo Collana Monogr; 1984; 1(2):139-46. PubMed ID: 6085885
    [No Abstract]   [Full Text] [Related]  

  • 36. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigen chimaeras of poliovirus as potential new vaccines.
    Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
    Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Location and primary structure of a major antigenic site for poliovirus neutralization.
    Minor PD; Schild GC; Bootman J; Evans DM; Ferguson M; Reeve P; Spitz M; Stanway G; Cann AJ; Hauptmann R; Clarke LD; Mountford RC; Almond JW
    Nature; 1983 Feb; 301(5902):674-9. PubMed ID: 6186919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antigenic N to H conversion of poliovirus by a monoclonal antibody at low ionic strength.
    Delaet I; Vrijsen R; Boeyé A
    Virology; 1992 May; 188(1):93-101. PubMed ID: 1314469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4.
    Minor PD; Ferguson M; Katrak K; Wood D; John A; Howlett J; Dunn G; Burke K; Almond JW
    J Gen Virol; 1991 Oct; 72 ( Pt 10)():2475-81. PubMed ID: 1717641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.